Greenstone Biosciences

Greenstone Biosciences is a private, pre-revenue biotech company founded in 2019, operating at the intersection of human iPSC technology and AI for drug discovery. Its core asset is a massive, clinically diverse iPSC biobank, which it uses to produce differentiated cells, complex organoids, and micro-physiological systems for high-throughput screening and toxicity testing. The company's integrated platform aims to reduce reliance on animal models, de-risk drug development, and accelerate therapies to market through human-relevant data. Greenstone offers both products (cells/organoids) and discovery services, positioning itself as a partner for pharmaceutical and academic research.

Integrated platform combining the world's largest human iPSC biobank (2,500+ donors) for generating differentiated cells and 3D organoids with a proprietary AI/ML engine (ADMET-AI) for predictive drug discovery and toxicity screening.

Greenstone operates in a competitive space that includes other iPSC-focused companies (e.g., bit.bio, Censo Biotechnologies, Ncardia), organoid specialists, and large CROs/tool providers (e.g., Charles River, Thermo Fisher) developing human-relevant models. Its differentiation lies in the scale and diversity of its foundational iPSC biobank and the tight integration of its biological data generation with its proprietary AI platform.